Bellicum Pharma is a clinical-stage company dedicated to developing innovative cellular immunotherapies for specific cancers and rare inherited blood disorders. With a strong focus on chimeric antigen receptor (CAR) cell therapy, Bellicum has engineered powerful and high-performance cellular immunotherapies to address a wide range of cancers, aiming to impact the lives of more patients than ever before. Their cutting-edge cellular platform technology is designed to overcome significant clinical barriers and unleash the full potential of cellular immunotherapies.

Bellicum's proprietary GoCAR™ technology plays a key role in their investigational immunotherapies, paving the way for durable patient responses in the future of cellular immuno-oncology (IO). Bellicum is committed to advancing their pipeline and has been actively involved in clinical trials to evaluate the safety and efficacy of their therapies. Their recent successes include reporting biochemical and radiographic responses in heavily pre-treated metastatic castration-resistant prostate cancer patients.

With a strong track record of scientific publications and a dedicated leadership team, Bellicum Pharma is poised to revolutionize the field of cellular IO and make a significant impact in the lives of cancer patients worldwide